Table 3.
In vivo pharmacokinetic parameters of DCT in rats after intravenous injection at a dose of 1 mg/kg
| Parameter | Taxotere® | PS-PDLLA/DCT NPs |
|---|---|---|
| AUC (μg·min/mL) | 10.18±1.09 | 23.56±1.70* |
| t1/2 (min) | 57.86±8.84 | 134.72±15.92* |
| CL (mL/min/kg) | 99.03±10.15 | 42.60±3.22* |
| Vss (mL/kg) | 1864.31±617.62 | 3260.97±957.80 |
| MRT (min) | 18.52±4.59 | 77.12±25.39* |
Notes: Data are presented as means ± SD (n≥3). The weight ratio between PS-PDLLA and DCT was 10:1 in the PS-PDLLA/DCT NPs group.
*
P<0.05 compared to Taxotere® (Sanofi S.A., Paris, France) group.
Abbreviations: AUC, total area under the plasma concentration-time curve from time zero to infinity; CL, time-averaged total body clearance; DCT, docetaxel; MRT, mean residence time; NP, nanoparticle; PS-PDLLA, poly(styrene)-b-poly(DL-lactide); SD, standard deviation; t1/2, terminal half-life; Vss, apparent volume of distribution at steady state.